This is an unofficial archive of PsychonautWiki as of 2025-08-11T15:14:44Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.
Gabapentin: Difference between revisions
>Rosie m →Subjective effects: it previously said its not very good at relieving acute pain, such as opiates which, although isnt hard to get what was meant when read literally is referring to opiates as a type of acute pain, or maybe just that opiates arent good for acute pain. i changed this to reflect what i assume was meant, that it's not effective unlike opiates, which are well known to be effective pain relief. |
>Gabagaba This line references a study on "gabapentin enacarbil", which is not the same as gabapentin. |
||
| Line 6: | Line 6: | ||
Gabapentin was originally developed to treat epilepsy and is currently FDA approved to treat postherpetic neuralgia in adults and as an adjunctive therapy in the treatment of partial onset seizures. It is often prescribed off-label for [[restless leg syndrome]], social anxiety disorder, panic disorder, and generalized anxiety disorder.<ref>Manual of Clinical Psychopharmacology | https://books.google.co.uk/books?id=D3zz1NCm3qcC&pg=PA345&hl=en</ref><ref>Successful Psychopharmacology: Evidence-Based Treatment Solutions for Achieving Remission | https://books.google.co.uk/books?id=dnAlO_Veu2QC&pg=PA124&hl=en</ref><ref>https://books.google.co.uk/books?id=82oiYYHGNTQC&pg=PA765&hl=en</ref> However Gabapentin's efficacy in the treatment of anxiety disorders is unclear as the evidence is "somewhat mixed".<ref>[https://www.ncbi.nlm.nih.gov/pubmed/17502773] The role of anticonvulsants in anxiety disorders: a critical review of the evidence.</ref><ref>[https://www.jmcp.org/doi/abs/10.18553/jmcp.2002.8.4.266] Gabapentin Use in a Managed Medicaid Population</ref><ref>[https://annals.org/aim/fullarticle/727539/narrative-review-promotion-gabapentin-analysis-internal-industry-documents] Promotion of Gabapentin</ref><ref>Restless legs syndrome: clinical presentation diagnosis and treatment | http://www.sleep-journal.com/article/S1389-9457(15)00647-4/abstract</ref> It is recommended as a first line agent for the treatment of neuropathic pain arising from diabetic neuropathy, post-herpetic neuralgia, and central neuropathic pain.<ref>EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/20402746</ref> | Gabapentin was originally developed to treat epilepsy and is currently FDA approved to treat postherpetic neuralgia in adults and as an adjunctive therapy in the treatment of partial onset seizures. It is often prescribed off-label for [[restless leg syndrome]], social anxiety disorder, panic disorder, and generalized anxiety disorder.<ref>Manual of Clinical Psychopharmacology | https://books.google.co.uk/books?id=D3zz1NCm3qcC&pg=PA345&hl=en</ref><ref>Successful Psychopharmacology: Evidence-Based Treatment Solutions for Achieving Remission | https://books.google.co.uk/books?id=dnAlO_Veu2QC&pg=PA124&hl=en</ref><ref>https://books.google.co.uk/books?id=82oiYYHGNTQC&pg=PA765&hl=en</ref> However Gabapentin's efficacy in the treatment of anxiety disorders is unclear as the evidence is "somewhat mixed".<ref>[https://www.ncbi.nlm.nih.gov/pubmed/17502773] The role of anticonvulsants in anxiety disorders: a critical review of the evidence.</ref><ref>[https://www.jmcp.org/doi/abs/10.18553/jmcp.2002.8.4.266] Gabapentin Use in a Managed Medicaid Population</ref><ref>[https://annals.org/aim/fullarticle/727539/narrative-review-promotion-gabapentin-analysis-internal-industry-documents] Promotion of Gabapentin</ref><ref>Restless legs syndrome: clinical presentation diagnosis and treatment | http://www.sleep-journal.com/article/S1389-9457(15)00647-4/abstract</ref> It is recommended as a first line agent for the treatment of neuropathic pain arising from diabetic neuropathy, post-herpetic neuralgia, and central neuropathic pain.<ref>EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/20402746</ref> | ||
[[Subjective effects]] include mild to moderate [[anxiety suppression]], [[pain relief]], and [[muscle relaxation]]. Its analgesic and anxiolytic effects provide gabapentin with some recreational potential in a manner that can be compared to a mild [[benzodiazepine]]. However, these recreational effects diminish very quickly with repeated usage and are most commonly reported by those who do not have a tolerance to this compound. | [[Subjective effects]] include mild to moderate [[anxiety suppression]], [[pain relief]], and [[muscle relaxation]]. Its analgesic and anxiolytic effects provide gabapentin with some recreational potential in a manner that can be compared to a mild [[benzodiazepine]]. However, these recreational effects diminish very quickly with repeated usage and are most commonly reported by those who do not have a tolerance to this compound. | ||
Gabapentin is considered to have low abuse potential compared to most recreational depressants. However, chronic use can lead to physical dependence. Additionally, there is a risk of lethal overdose when it is combined with other depressants (a relatively common practice considering its weak effects). As a result, it is highly advised to use [[harm reduction practices]] if using this substance. | Gabapentin is considered to have low abuse potential compared to most recreational depressants. However, chronic use can lead to physical dependence. Additionally, there is a risk of lethal overdose when it is combined with other depressants (a relatively common practice considering its weak effects). As a result, it is highly advised to use [[harm reduction practices]] if using this substance. | ||